FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  ALTSTIEL LARRY DOUGLAS
 2. Date of Event Requiring Statement (Month/Day/Year)
07/07/2022		 3. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [PMN]
(Last)
(First)
(Middle)
C/O PROMIS NEUROSCIENCES INC.,, 1920 YONGE STREET, SUITE 200		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Medical Officer
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

TORONTO, A6 M4S 3E2		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Option (right to buy)   (2) 02/10/2032 Common Shares 2,500 $ 8.4 (1) D  
Option (right to buy)   (3) 04/14/2032 Common Shares 30,833 $ 7.2 (1) D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
ALTSTIEL LARRY DOUGLAS
C/O PROMIS NEUROSCIENCES INC.,
1920 YONGE STREET, SUITE 200
TORONTO, A6 M4S 3E2		       Chief Medical Officer  

Signatures

/s/ Jason L. Langford, Attorney-in-Fact for Larry Douglas Altstiel 07/07/2022
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Conversion or exercise price is in Canadian dollars.
(2) The option agreement provides that 833 options vest immediately upon grant, with the balance vesting equally over 24 months. The option was granted on February 10, 2022.
(3) The option agreement provides that the options become exercisable in 48 equal monthly installments beginning one month after the grant. The option was granted on April 14, 2022.
 
Remarks:
Exhibit List: Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.